# EDGAR Filing Document

**Accession Number:** 0001726445
**File Stem:** 0001193125-26-235517
**Filing Date:** 2026-5
**Character Count:** 10345
**Document Hash:** 7306bcaf77975bceb9d6a6660d7be0a8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-235517.hdr.sgml**: 20260522

**ACCESSION NUMBER**: 0001193125-26-235517

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20260521

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260522

**DATE AS OF CHANGE**: 20260522

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Seer, Inc.
- **CENTRAL INDEX KEY:** 0001726445
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 821153150
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39747
- **FILM NUMBER:** 261010829

**BUSINESS ADDRESS:**
- **STREET 1:** 3800 BRIDGE PARKWAY, SUITE 102
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065
- **BUSINESS PHONE:** 650-453-0000

**MAIL ADDRESS:**
- **STREET 1:** 3800 BRIDGE PARKWAY, SUITE 102
- **CITY:** REDWOOD CITY
- **STATE:** CA
- **ZIP:** 94065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Seer Biosciences, Inc.
- **DATE OF NAME CHANGE:** 20171226

?xml version='1.0' encoding='ASCII'? 8-K

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** 

May 21, 2026

------

Seer, Inc.

**(Exact name of registrant as specified in its charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-39747 | 82-1153150 |
| **(State or other jurisdiction of** | **(Commission** | **(I.R.S. Employer** |
| **incorporation)** | **File Number)** | **Identification No.)** |

---

3800 Bridge Parkway**,** Suite 102

Redwood City**,** California 94065

**(Address of principal executive offices, including zip code)**

650**-**453-0000

**(Registrant's telephone number, including area code)**

**Not Applicable**

**(Former name or former address, if changed since last reports)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

---

| | |
|:---|:---|
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☒ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |

---

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Class A Common Stock, par value $0.00001 per share | SEER | The NASDAQ Global Select Market |
| Preferred Stock Purchase Rights | N/A | The NASDAQ Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.** |

---

On May 21, 2026, Seer, Inc. issued a press release concerning the further revised highly contingent, non-binding and unsolicited acquisition proposal received from Bradley L. Radoff, Michael Torok and certain of their affiliates on May 14, 2026.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

------

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [<u>99.1</u>](ck0001726445-ex99_1.htm) | Press Release dated May 21, 2026, titled "Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal from Radoff-JEC Group." |
| 104 | Cover Page from this Current Report on Form 8-K, formatted in Inline XBRL. |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **SEER, INC.** | **SEER, INC.** |
| Date: May 22, 2026 | By: | <u>/s/ David Horn</u> |
|  |  | David Horn |
|  |  | President and Chief Financial Officer |

---

------

## Exhibit 99.1

**Seer Board of Directors Unanimously Rejects Further Revised Unsolicited Proposal** 

**from Radoff-JEC Group**

**REDWOOD CITY, Calif., May 21, 2026 –** Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors (the "Board") has thoroughly reviewed and unanimously rejected the further revised unsolicited non-binding proposal received on May 14, 2026, from Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group"), to acquire all of the outstanding shares of Seer's Class A common stock for $2.40 per share in cash plus a contingent value right (the "May 14 Revised Proposal").

Consistent with its fiduciary duties, the Board carefully reviewed the May 14 Revised Proposal in consultation with its independent financial and legal advisors and unanimously determined it is not in the best interests of Seer stockholders because it significantly undervalues Seer and fails to reflect the value of Seer's long-term growth prospects. The May 14 Revised Proposal is materially the same as the proposal that the Board thoroughly reviewed and rejected on April 27, 2026. As with the prior proposals submitted by the Radoff-JEC Group, the May 14 Revised Proposal continues to imply an equity value for Seer that is meaningfully below the sum of Seer's current cash, cash equivalents and investments.

Perella Weinberg Partners LP is serving as financial advisor to Seer, and Wilson Sonsini Goodrich & Rosati, Professional Corporation is serving as legal counsel.

**About Seer, Inc.**

Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer's Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer's products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.

For more information, please email us at pr@seer.bio.<br>**Additional Information and Where to Find It**

On May 18, 2026, Seer filed a preliminary proxy statement in connection with its 2026 Annual Meeting of Stockholders (the "Annual Meeting"), which is available [<u>here</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001726445/000119312526229128/ck0001726445-20260518.htm). Detailed information regarding the names, affiliations and interests of individuals who are participants in Seer's solicitation of proxies from its stockholders is available in Seer's preliminary proxy statement. Prior to the Annual Meeting, Seer will furnish a definitive proxy statement to its stockholders, together with a BLUE proxy card. STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.

Stockholders may obtain, free of charge, Seer's proxy statement (in both preliminary and definitive form), any amendments or supplements thereto, and any other relevant documents filed by Seer with the Securities and Exchange Commission (the "SEC") in connection with the Annual Meeting at the SEC's website, which is located at https://www.sec.gov. Copies of Seer's definitive 2026 proxy statement, any amendments or supplements thereto and any other relevant documents filed by Seer with the SEC in connection with the Annual Meeting will also be available, free of charge, at Seer's website, which is located at https://investor.seer.bio/, or by writing to Investor Relations, Seer, Inc., 3800 Bridge Parkway, Suite 102, Redwood City, CA 94065. In addition, copies of these materials may be requested, free of charge, from Seer's proxy solicitor by calling Innisfree M&A Incorporated at (877) 456-3524.

------

**Forward-Looking Statements**

This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer's actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer's prospects. These and other risks are described more fully in Seer's filings with the SEC and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

**Media Contact:**<br>Patrick Schmidt<br>pr@seer.bio

Joele Frank, Wilkinson Brimmer Katcher<br>Eric Brielmann / Joseph Sala<br>(212) 355-4449

**Investor Contact:**<br>Marissa Bych<br>investor@seer.bio

------